Chase Investment Counsel’s Catalyst Pharmaceutical CPRX Stock Holding History

Chase Investment Counsel’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.49M	Hold	60,000	–	–	0.39%	64
2025 Q4	$1.4M	Hold	60,000	–	–	0.39%	58
2025 Q3	$1.18M	Buy	60,000 +6,000	+11%	+$123K	0.35%	64
2025 Q2	$1.17M	Hold	54,000	–	–	0.37%	61
2025 Q1	$1.31M	Hold	54,000	–	–	0.48%	57
2024 Q4	$1.13M	Buy	+54,000	New	+$1.16M	0.36%	64

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Chase Investment Counsel's CPRX Position: Q1 2026 in Review

Chase Investment Counsel held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 60,000 shares worth $1.49M. The position accounts for 0.39% of the portfolio, ranked #64.

Chase Investment Counsel first reported a position in CPRX in Q4 2024 and has held it in 6 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Chase Investment Counsel held 60,000 shares of Catalyst Pharmaceutical worth $1.49M as of Q1 2026.
Chase Investment Counsel left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
Catalyst Pharmaceutical made up 0.39% of Chase Investment Counsel's portfolio in Q1 2026, its #64 holding.
Chase Investment Counsel first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Chase Investment Counsel's 13F filing for Q1 2026, filed 12 May 2026.